Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$15.45 ▼ -0.11
(-0.71%)
MKT CAP: $994.3M • VOL: 460.1K
52W L $7 52W H $23
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
CGEM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$241.6M | -$196.9M | -$191.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$219.9M | -$167.6M | -$155.1M |
| EBITDA (Normalized) | -$241.6M | -$196.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$175.8M | -$145.3M | -$134.3M |
| Capital Expenditures (CapEx) | $49.0K | $0 | — |
| Free Cash Flow (FCF) | -$175.8M | -$145.3M | -$134.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -30.7% | — |
| Cash & Short-Term Equivalents | $88.3M | $83.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $408.7M | $590.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CGEM.